Recruiting · registry status

Testing a supplement in a related movement disorder

This study examines whether a supplement called tributyrin is safe and manageable for people with progressive supranuclear palsy, a condition distinct from Parkinson’s.

Testing a treatment or activity · Study reference: NCT07863180

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Who can join?

Age 45 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Male or Female, age 45 years and over. * Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including 1. Vertical supranuclear gaze palsy. 2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years. * Access to the internet and webcam for virtual visits. * Presence of a caregiver. Exclusion Criteria: * Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer. * Significant metabolic or uncontrolled medical comorbidity. * Regular use of typical anti-cholinergic drugs. * Women of child-bearing potential, or who are pregnant and/or nursing. * Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. * Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.

Full study name & original research details

Official study title

Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study

Short title used by the registry

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Original description

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Further description from the registry

This is a sub-study of NCT07154511.

Conditions reported: Parkinson Disease; Multiple System Atrophy; Progressive Supranuclear Palsy(PSP)

Study type: Interventional
Interventions: Tributyrin; Placebo
Phases: PHASE1; PHASE2
Sponsor: Prabesh Kanel
Start date reported by registry: 2026-09 (estimated)

Registry updated: 2026-10-07 · Status last verified by the registry submitter: 2026-10

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Nathan Alexander · 734-998-8422 · natealex@med.umich.edu

Robert Vangel, BSc · 734-936-1168 · rvangel@med.umich.edu

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Domino's Farms

Ann Arbor, Michigan, United States

Recruiting

Nathan Alexander · 734-998-8422 · natealex@med.umich.edu

Robert Vangel, BSc · 734-936-1168 · rvangel@med.umich.edu

Prabesh Kanel, PhD

Nicolaas Bohnen, MD, PhD

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.